Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Distinguishing Features of MOG Positive and MOG Negative Pediatric Patients with ADEM
Child Neurology and Developmental Neurology
S2 - Child Neurology and Developmental Neurology 1 (2:24 PM-2:36 PM)
008

MOG antibody disease is an increasingly recognized etiology for acute disseminated encephalomyelitis (ADEM). ADEM is a condition that predominately affects children and presents with multifocal neurological symptoms and encephalopathy. Positive MOG antibodies strongly argues against later development of multiple sclerosis or NMOSD. The distinguishing characteristics of ADEM, as defined by MOG positive or negative status has not been well studied.

To compare MOG positive and negative patients with ADEM as relates to demographic features, neuroimaging and laboratory features, hospital course, treatments, and relapse rate.

Children with the initial diagnosis of ADEM were consented to participate in a study of ADEM related outcomes. Their demographic features, clinical presentation, laboratory and imaging results, and clinical course are presented, highlighting differences in MOG positive and negative cohorts.

37 children in the study were assessed for MOG IgG. 18 children were MOG positive (49%) and 19 children were MOG negative (51%). Average age and race/ethnicity were similar between cohorts but the MOG positive group showed equal male/female ratio while MOG negative cohort showed male predominance (74%).

The MOG negative cohort had greater number of individuals with normal nucleated cells in CSF (0-5 cells/mm3) than MOG positive cohort: 7/19 (37%) vs 2/18 (11%). Neuroimaging features, need for ICU stay and acute rehabilitation were similar between cohorts. A greater number of MOG positive patients required ICP management (4/18 vs 1/19) and one MOG positive child died.

6/18 (33%) MOG positive patients had relapses compared to 3/19 (16%) MOG negative patients. 90% of the 29 patients who had neuropsychological testing scored within the normal range.

 

MOG antibody disease is a common cause of ADEM though the characteristics of MOG positive and negative ADEM patients have not been well described. This study compares these populations from our tertiary center's cohort of ADEM patients enrolled in an ADEM study.
Authors/Disclosures
Cynthia X. Wang, MD (Children's Dallas Neurology)
PRESENTER
Dr. Wang has nothing to disclose.
Patricia Plumb Patricia Plumb has nothing to disclose.
Lana Harder, PhD (Children'S Medical Center, Dallas/UT Southwestern) Dr. Harder has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis Pharmaceuticals.
Benjamin M. Greenberg, MD, FAAN (UT Southwestern Medical Center) Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/ROche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle Pharma. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has stock in GenrAb. Dr. Greenberg has stock in Clene. The institution of Dr. Greenberg has received research support from CLENE Nanomedicine. The institution of Dr. Greenberg has received research support from Anokion. The institution of Dr. Greenberg has received research support from Regeneron. Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.